B. Riley raised the firm’s price target on Syndax to $36 from $34 and keeps a Buy rating on the shares after the company unveiled top-line data for the AGAVE-201 trial, which evaluated axatilimab for chronic graft versus host disease. Axatilimab’s profile is emerging as highly competitive in the treatment landscape for cGVHD, the analyst tells investors in a research note. The firm forecasts the drug will transition as an important post second-line agent following potential regulatory approval next year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SNDX:
- Syndax price target raised to $42 from $40 at Guggenheim
- Syndax and Incyte report topline data from the pivotal AGAVE-201 trial
- Syndax initiated with Buy on ‘compelling’ data at Guggenheim
- Syndax initiated with a Buy at Guggenheim
- BTIG biotechnology analyst to hold an analyst/industry conference call